* | Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 111817 Search Results for

*

Sort by

Sort Order Select

Journal Articles

Assessing Pre-Operative Bleeding Risk Using INR/aPTT: A Systematic Review

Hassan Rahhal, Brandon Christopher Tse, Grace Tang, Michael Fralick, Lisa Hicks, Michelle Sholzberg

Blood (2023) 142 (Supplement 1): 2318.

https://doi.org/10.1182/blood-2023-185358

Published: 2023

Journal Articles

Immune-Related Gene Expression Signatures Identify a Patient's Subset Achieving Durable Complete Response to Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma

Paulina Nierychlewska, Maria Rosaria Sapienza, Alessandro Davini, Eugenia Montanari, Anna Vanazzi, Simonetta Viviani, Valentina Tabanelli, Roberto Massimo Lemoli, Corrado Tarella, Stefano Pileri, Enrico Derenzini

Blood (2023) 142 (Supplement 1): 1644.

https://doi.org/10.1182/blood-2023-186819

Published: 2023

Journal Articles

18F-FDG PET/CT Imaging Biomarkers for CAR-T Cell Therapy Outcomes in Large-B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 1639.

https://doi.org/10.1182/blood-2023-179641

Published: 2023

Journal Articles

The Impact of KIR-HLA Interplay in T-LGL Leukemia

Aashray Mandala, Carlos Bravo-Perez, Nakisha D Williams, Christopher Haddad, Luca Guarnera, Simona Pagliuca, Serhan Unlu, Yasuo Kubota, Naomi Kawashima, Carmelo Gurnari, Valeria Visconte, Arda Durmaz, Jaroslaw P. Maciejewski

Blood (2023) 142 (Supplement 1): 1637.

https://doi.org/10.1182/blood-2023-189268

Published: 2023

Journal Articles

Refining Diagnostic Subtypes of Peripheral T-Cell Lymphoma Using a Multiparameter Approach

Blood (2023) 142 (Supplement 1): 1636.

https://doi.org/10.1182/blood-2023-186950

Published: 2023

Journal Articles

Resistance Mechanisms Impacting Bispecific Antibody (BsAbs) and Chimeric Antigen Receptor (CAR) T-Cell Therapy Outcomes in Large B Cell Lymphoma (LBCL) Patients

Blood (2023) 142 (Supplement 1): 1635.

https://doi.org/10.1182/blood-2023-186072

Published: 2023

Journal Articles

Tumor Mutational Burden As a Prognostic Factor in Diffuse Large B-Cell Lymphoma

Rosalie Griffin, Kerstin Wenzl, Vivekananda Sarangi, Lisa M. Rimsza, Rebecca King, Andrew L. Feldman, Matthew J. Maurer, Grzegorz S. Nowakowski, Brian K. Link, Thomas M. Habermann, Nicholas Stong, C. Chris Huang, Anita K. Gandhi, Susan L. Slager, Anne J. Novak, James R. Cerhan

Blood (2023) 142 (Supplement 1): 1633.

https://doi.org/10.1182/blood-2023-182291

Published: 2023

Journal Articles

Whole Exome Sequencing Analysis of Diffuse Large B-Cell Lymphoma That Progressed to Central Nervous System

Tomotaka Suzuki, Rui Yokomori, Takaomi Sanda, Hiroki Yano, Takaki Kikuchi, Takashi Kanamori, Atsushi Inagaki, Takashi Yoshida, Satoshi Kayukawa, Yoshiko Oshima, Hirokazu Sasaki, Shiori Kinoshita, Tomoko Narita, Ayako Masaki, Masaki Ri, Shigeru Kusumoto, Hirokazu Komatsu, Hiroshi Inagaki, Shinsuke Iida

Blood (2023) 142 (Supplement 1): 1632.

https://doi.org/10.1182/blood-2023-174341

Published: 2023

Journal Articles

Identification of High-Risk Population in First-Line Follicular Lymphoma at Screening with a Next Generation Sequencing (NGS) Assay Using Plasma Circulating Tumor DNA (ctDNA): Initial Data from Gallium

Alessia Bottos, Corinna Woestmann, Christopher R. Bolen, Maria Shin, Patrick Bogard, Ehsan Tabari, Andrew S. Davies, Andrea Knapp, Tina Nielsen, Oliver Weigert, Elicia Penuel

Blood (2023) 142 (Supplement 1): 1629.

https://doi.org/10.1182/blood-2023-181723

Published: 2023

Journal Articles

Genetic Knockin Approaches to Reconstructing DLBCL-Subtypes from Human Germinal Center B-Cells

Dhruv Khanduja, Mark E Robinson, David Fonseca Arce, Lars Klemm, Etienne Leveille, Shalin Kothari, Rebecca Caeser, Daniel James Hodson, Markus Müschen

Blood (2023) 142 (Supplement 1): 1627.

https://doi.org/10.1182/blood-2023-190634

Published: 2023

Journal Articles

The ELN 2022 Risk Stratification Has No Impact on the Dismal Prognosis of Patients with Acute Undifferentiated Leukemia

Baher Krayem, Tsila Zuckerman, Avraham Frisch, Ilana Slouzkey, Tehila Azoulay, Michal Karmona, Liran I. Shlush, Nathali Kaushansky, Noa Chapal-Ilani, Shimrit Ringelstein-Harlev

Blood (2023) 142 (Supplement 1): 4221.

https://doi.org/10.1182/blood-2023-188592

Published: 2023

Journal Articles

AML Treatment By the AXL Inhibitor Bemcentinib in Combination with Cytarabine Shows Clinical Efficacy Related to TNFα and Cytotoxic Immune Cells: A Single-Cell Translational Study from the BGBC003 Trial

Blood (2023) 142 (Supplement 1): 1540.

https://doi.org/10.1182/blood-2023-185499

Published: 2023

Journal Articles

Updated Results from Phase 1 Study of Targeted Radiotherapy with Lintuzumab-Ac225 in Combination with Venetoclax in Relapsed/Refractory AML

Gail J. Roboz, Laura E. Finn, Johnnie J. Orozco, Mohamed Hegazi, Avinash Desai, Mary Chen, Gary J. Schiller

Blood (2023) 142 (Supplement 1): 1539.

https://doi.org/10.1182/blood-2023-178802

Published: 2023

Journal Articles

Oral Decitabine/Cedazuridine Vs Intravenous Decitabine for Acute Myeloid Leukemia: Final Results of a Randomized, Crossover, Registration-Enabling, Pharmacokinetics Study

Blood (2023) 142 (Supplement 1): 1538.

https://doi.org/10.1182/blood-2023-173092

Published: 2023

Journal Articles

Dose Escalation of HLA-A2-WT1 CD3 T-Cell Bispecific Antibody in a Phase I Study in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Blood (2023) 142 (Supplement 1): 1537.

https://doi.org/10.1182/blood-2023-173302

Published: 2023

Journal Articles

I-DATA Study: Randomized, Sequential, Open-Label Study to Evaluate the Efficacy of IDH Targeted/Non- Targeted Versus Non-Targeted/IDH-Targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated Adult AML Patients Not Candidates for Intensive Induction Therapy

Michael P Ozga, Kaitlyn M. Dvorak-Kornaus, Qiuhong Zhao, Jill Buss, Andrea Laganson, Ethan Hamp, Yazan F. Madanat, Daniel A. Pollyea, Eytan M. Stein, Joshua F. Zeidner, Elaine R Mardis, Ann-Kathrin Eisfeld, Alice Mims

Blood (2023) 142 (Supplement 1): 1534.

https://doi.org/10.1182/blood-2023-187060

Published: 2023

Journal Articles

Comparison of Safety and Efficacy between Venetoclax Combined with CAG (cytarabine, aclarubicin, G-CSF) Regimen and CAG Regimen Alone in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Wen-Jing Yu, Ying Wu, Qi Chen, Xiaolu Zhu, Xu-Ying Pei, Jin-Song Jia, Jing Wang, Xiao-Su Zhao, Ying-Jun Chang, Yue-Yun Lai, Hong-Xia Shi, Guo-Rui Ruan, Ya-Zhen Qin, Xiao-Hong Liu, Xiao Jun Huang, Hao Jiang

Blood (2023) 142 (Supplement 1): 1525.

https://doi.org/10.1182/blood-2023-184665

Published: 2023

Journal Articles

Prognostic Utility of the Patient-Derived AML Cells' Ex Vivo Drug Sensitivity Results

Silvia Park, Sung-Soo Park, Byoung Sik Cho, Sungwon Lim, Kwan Hyun Kim, Gyucheol Choi, Seunghyeok Ham, Seongjoon Lee, Sesun Park, Gunjae Lee, Junyoung Lee, Edward Song, Jamin Koo, Heeje Kim

Blood (2023) 142 (Supplement 1): 1523.

https://doi.org/10.1182/blood-2023-183056

Published: 2023

Journal Articles

Preoperative Exchange Transfusion for Patients with SCD Systematic Review

Yasamin Abdu, Alaa Rahhal, Khalid Ahmed, Elrazi Ali, Mohamed A Yassin

Blood (2023) 142 (Supplement 1): 5292.

https://doi.org/10.1182/blood-2023-172602

Published: 2023

Journal Articles

Increased Risk for Hospitalization Associated with Short Term Particle Air Pollution Exposure for California Residents with Sickle Cell Disease

Shaina Willen, Ann Brunson, Yaguang Wei, Olubusola Oluwole, Oyebimpe Adesina, Ted Wun

Blood (2023) 142 (Supplement 1): 5291.

https://doi.org/10.1182/blood-2023-189804

Published: 2023

NARROW

*

Assessing Pre-Operative Bleeding Risk Using INR/aPTT: A Systematic Review

Immune-Related Gene Expression Signatures Identify a Patient's Subset Achieving Durable Complete Response to Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma

18F-FDG PET/CT Imaging Biomarkers for CAR-T Cell Therapy Outcomes in Large-B-Cell Lymphoma

The Impact of KIR-HLA Interplay in T-LGL Leukemia

Refining Diagnostic Subtypes of Peripheral T-Cell Lymphoma Using a Multiparameter Approach

Resistance Mechanisms Impacting Bispecific Antibody (BsAbs) and Chimeric Antigen Receptor (CAR) T-Cell Therapy Outcomes in Large B Cell Lymphoma (LBCL) Patients

Tumor Mutational Burden As a Prognostic Factor in Diffuse Large B-Cell Lymphoma

Whole Exome Sequencing Analysis of Diffuse Large B-Cell Lymphoma That Progressed to Central Nervous System

Identification of High-Risk Population in First-Line Follicular Lymphoma at Screening with a Next Generation Sequencing (NGS) Assay Using Plasma Circulating Tumor DNA (ctDNA): Initial Data from Gallium

Genetic Knockin Approaches to Reconstructing DLBCL-Subtypes from Human Germinal Center B-Cells

The ELN 2022 Risk Stratification Has No Impact on the Dismal Prognosis of Patients with Acute Undifferentiated Leukemia

AML Treatment By the AXL Inhibitor Bemcentinib in Combination with Cytarabine Shows Clinical Efficacy Related to TNFα and Cytotoxic Immune Cells: A Single-Cell Translational Study from the BGBC003 Trial

Updated Results from Phase 1 Study of Targeted Radiotherapy with Lintuzumab-Ac225 in Combination with Venetoclax in Relapsed/Refractory AML

Oral Decitabine/Cedazuridine Vs Intravenous Decitabine for Acute Myeloid Leukemia: Final Results of a Randomized, Crossover, Registration-Enabling, Pharmacokinetics Study

Dose Escalation of HLA-A2-WT1 CD3 T-Cell Bispecific Antibody in a Phase I Study in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

I-DATA Study: Randomized, Sequential, Open-Label Study to Evaluate the Efficacy of IDH Targeted/Non- Targeted Versus Non-Targeted/IDH-Targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated Adult AML Patients Not Candidates for Intensive Induction Therapy

Comparison of Safety and Efficacy between Venetoclax Combined with CAG (cytarabine, aclarubicin, G-CSF) Regimen and CAG Regimen Alone in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Prognostic Utility of the Patient-Derived AML Cells' Ex Vivo Drug Sensitivity Results

Preoperative Exchange Transfusion for Patients with SCD Systematic Review

Increased Risk for Hospitalization Associated with Short Term Particle Air Pollution Exposure for California Residents with Sickle Cell Disease

Email alerts

ASH Publications

American Society of Hematology

*

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only